Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | TAF1 | P21675 | 1/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30261030 | 0.80 | BRD4 (0.45) | MEN1POLBKMT2AMAPK1KDM4E | |
| SCHEMBL7835424 | 0.80 | BRD4 (0.45) | MEN1POLBKMT2AMAPK1KDM4E | |
| SCHEMBL9315426 | 0.78 | MCL1 (0.42) | MEN1POLBKMT2AMAPTMAPK1 | |
| SCHEMBL17659906 | 0.78 | TNF (0.53) | MEN1POLBKMT2AMAPTMAPK1 | |
| SCHEMBL21831548 | 0.78 | HTR2A (0.42) | MEN1POLBKMT2AMAPK1BRD4 | |
| SCHEMBL917801 | 0.75 | TNF (0.39) | MEN1POLBKMT2AMAPK1KDM4E | |
| SCHEMBL25210536 | 0.74 | PRKCQ (0.39) | MEN1POLBKMT2AMAPTMAPK1 | |
| SCHEMBL29713816 | 0.74 | TNF (0.42) | MEN1POLBKMT2AMAPTMAPK1 | |
| SCHEMBL6097464 | 0.74 | TNF (0.42) | MEN1POLBKMT2AMAPTMAPK1 | |
| SCHEMBL594125 | 0.73 | BCHE (0.56) | MAPTMAPK1KDM4ENR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230127-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-12172959-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| CN-113045476-B | Monosubstituted or disubstituted indole derivatives as dengue virus replication inhibitors | 杨森制药公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240182414-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2024-06-06 | — | — | US | disclosed |
| CN-111303000-B | Monosubstituted or disubstituted indole derivatives as dengue virus replication inhibitors | 杨森制药公司 | 2023-11-28 | — | — | CN | disclosed |
| US-11827602-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827602-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827602-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| EP-3896072-B1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-3896072-B1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2022-11-16 | — | — | EP | disclosed |
| US-10696632-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10206902-B2 | Mono- or di-substituted indoles as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10206902-B2 | Mono- or di-substituted indoles as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180346419-A1 | Mono- or Di-Substituted Indole Derivatives As Dengue Viral Replication Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-06 | — | — | US | disclosed |
| EP-3201177-B1 | MONO- OR DI-SUBSTITUTED INDOLES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20170224658-A1 | Mono- or di-substituted indoles as dengue viral replication inhibitors | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-08-10 | — | — | US | disclosed |
| US-20170224658-A1 | Mono- or di-substituted indoles as dengue viral replication inhibitors | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-08-10 | — | — | US | disclosed |
| US-20170224658-A1 | Mono- or di-substituted indoles as dengue viral replication inhibitors | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-08-10 | — | — | US | disclosed |
| WO-2016180696-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016050831-A1 | MONO- OR DI-SUBSTITUTED INDOLES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346419-A1 | Mono- or Di-Substituted Indole Derivatives As Dengue Viral Replication Inhibitors | IDO1, IDO2, IRF3 | MEN1 1374/4885POLB 1729/4885KMT2A 1230/4885 |
| US-10696632-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | IDO1, IDO2, IRF3 | MEN1 1434/4885POLB 1648/4885KMT2A 1373/4885 |
| US-20250230127-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | IDO1, IDO2, IRF3 | MEN1 1374/4885POLB 1729/4885KMT2A 1230/4885 |
| US-11827602-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | IDO1, IDO2, IRF3 | MEN1 1434/4885POLB 1648/4885KMT2A 1373/4885 |
| US-20240182414-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | IDO1, IDO2, IRF3 | MEN1 1434/4885POLB 1648/4885KMT2A 1373/4885 |
| US-10206902-B2 | Mono- or di-substituted indoles as dengue viral replication inhibitors | IDO1, IDO2, INMT | MEN1 866/4885POLB 1246/4885KMT2A 1462/4885 |
| US-12172959-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | IDO1, IDO2, IRF3 | MEN1 1434/4885POLB 1648/4885KMT2A 1373/4885 |
| US-20170224658-A1 | Mono- or di-substituted indoles as dengue viral replication inhibitors | IDO1, IDO2, INMT | MEN1 866/4885POLB 1246/4885KMT2A 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.